Detoxification and biotransformational imbalances

Explore: The Journal of Science and Healing

Volumn 2, Issue 2, 2006, Pages 122-140

  Liska, DeAnn ^a   Lyon, Michael ^a   Jones, David S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CIMETIDINE; CLARITHROMYCIN; EPOXIDE HYDROLASE; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; ITRACONAZOLE; KETOCONAZOLE; MEPHENYTOIN; METHYLTRANSFERASE; NARINGENIN; NEFAZODONE; NEUROLEPTIC AGENT; NORFLUOXETINE; PARACETAMOL; PAROXETINE; PHENOBARBITAL; PROGUANIL; PROPAFENONE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERTRALINE; SULFOTRANSFERASE; TOLBUTAMIDE; TROLEANDOMYCIN; UNINDEXED DRUG; XENOBIOTIC AGENT;

AIR; BIOTRANSFORMATION; BODY BURDEN; BRAIN DISEASE; CARDIOVASCULAR SYSTEM; CHEMOSENSITIVITY; CHRONIC FATIGUE SYNDROME; COUNSELING; DEGENERATIVE DISEASE; DETOXIFICATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ELIMINATION; DRUG METABOLISM; EATING HABIT; ENDOCRINE FUNCTION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FOOD; FOOD INTAKE; GENETIC SUSCEPTIBILITY; GILBERT DISEASE; HEALTH PRACTITIONER; HEREDITY; HUMAN; IMMUNE SYSTEM; IMMUNOTOXICITY; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; METABOLITE; NERVOUS SYSTEM; PANCREATITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RESEARCH; REVIEW; RISK ASSESSMENT; SUPPLEMENTATION;

EID: 33644911463     PISSN: 15508307     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.explore.2005.12.009     Document Type: Article

References (162)

1. U.S. Environmental Protection Agency, 1987-1994. Toxics Release Inventory National Report, Washington, D.C.: Office of Toxic Substances.
2. The EPA website: http://www.epa.gov/All+chemicals&industry Last visited 5-09-2005.
3. J.E. Pizzorno M.T. Murray Detoxification: A naturopathic perspec-tive Nat Med J. 1 1998 6-17
4. R.W. Estabrook Cytochrome P450: From a single protein to a family of proteins with some personal reflections C. Ioannides Cytochromes P450: Metabolic and toxicological aspects 1996 CRC Press, Inc Boca Raton, FL 3-28
5. T. Omura Forty years of cytochrome P450 Biochem Biophys Res Commun. 266 3 1999 690-698
6. R.W. Estabrook A passion for P450s (remembrances of the early history of research on cytochrome P450) Drug Metab Disp. 31 2003 1461-1473
7. R.L. Smith R.T. Williams History of the discovery of the conjugation mechanisms W.H. Fishman Metabolic Conjugation and Metabolic Hydrolysis 1970 Academic Press New York
8. K. Levsen et. al. Structure elucidation of phase II metabolites by tandem mass spectrometry an overview J Chromatogr A 1067 1-2 2005 55-72
9. J.L. Dorne K. Walton A.G. Renwick Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: A review Food Chem Toxicol. 43 2 2005 203-216
10. A.K. Daly Pharmacogenetics of the cytochromes P450 Curr Top Med Chem. 4 16 2004 1733-1744
11. F.P. Guengerich Cytochromes P450, drugs, and diseases Mol Interv. 3 4 2003 194-204
12. J. Bland E. Barrager R. Reedy K. Bland A medical food-supple-mented detoxification program in the management of chronic health problems Altern Ther Health Med. 1 5 1995 62-71
13. G. Steventon M. Heafield R. Waring A. Williams Xenobiotic metabolism in Parkinson's disease Neurology 39 1989 883-887
14. Y. Huang et. al. Genetic contributions to Parkinson's disease Brain Res Brain Res Rev. 46 1 2004 44-70
15. T.M. Dawson V.L. Dawson Molecular pathways of neurodegenera-tion in Parkinson's disease Science 302 5646 2003 819-822
16. B. Ning C. Wang F. Morel et. al. Human glutathione S-transferase A2 polymorphisms: Variant expression, distribution in prostate cancer cases/ controls and a novel form Pharmacogenetics 14 1 2004 35-44
17. H.W. Mohrenweiser Genetic variation and exposure related risk estimate: will toxicology enter a new era? DNA repair and cancer as a paradigm Toxicol Pathol. 32 Suppl 1 2004 136-145
18. P. Chacko T. Joseph B.S. Mathew et. al. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treat-ment outcome Mutat Res. 581 1-2 2005 153-163
19. J.E. Plzzomo M.T. Murray Detoxification: A naturopathic perspective Nat Med J. 1 1998 6-17
20. D. Hoffman E. Lavoie S. Hecht Nicotine: A precursor for carcino-gens Cancer Letts. 26 1985 67-75
21. J.H. Weisburger Prevention of cancer and other chronic diseases worldwide based on sound mechanisms Biofactors 12 1-4 2000 73-81
22. Casarett & Doull's Toxicology The Basic Science of Poisons (6th Edition) 2004 McGraw-Hill Edited by: Klaassen CD;1236
23. J. Timbrell Principles of Biochemical Toxicology 2nd Ed. 1991 Taylor and Francis London
24. D. Grant Detoxification pathways in the liver J Inher Metab Dis. 14 1991 421-430
25. F.J. Gonzalez Role of cytochrome P450 in chemical toxicity and oxidative stress studies with CYP2E1 Mutat Res. 569 1-2 2005 101-110
26. D.E. Ryan A.Y.H. Lu J. Kawalek et. al. Highly purified cytochrome P448 and P450 from rat liver microsomes Biochem Biophys Res Commun. 64 1975 1134
27. T.L. Poulos B.C. Finzel I.C. Gunsalus et. al. 2.6-A crystal structure of Pseudomonas putida cytochrome P-450 J Biol Chem. 260 1985 16122-16130
28. F.J. Gonzalez J.R. Idle Pharmacogenetic phenotyping and genotyp-ing. Present status and future potential Clin Pharmacokinet 26 1994 59-70
29. M. Aguiar R. Masse B.F. Gibbs Regulation of cytochrome P450 by posttranslational modification Drug Metab Rev. 37 2 2005 379-404
30. H. Norppa Cytogenetic biomarkers and genetic polymorphisms Toxicol Lett. 149 1-3 2004 309-334
31. D.G. LeCouteur M. Muller M.C. Yang et. al. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease Rev Environ Health 17 1 2002 51-64
32. D. Bonneh-Barkay W.J. Langston D.A. DiMonte Toxicity of redox cycling pesticides in primary mesencephalic cultures Antioxid Redox Signal 7 5-6 2005 649-653
33. S. Rendic Summary of information on human CYP enzymes: Human P450 metabolism data Drug Metab Rev. 34 2002 83-448
34. D. Grant Detoxification pathways in the liver J Inher Metab Dis. 14 1991 421-430
35. H.A. Sampson Food hypersensitivity manifestations, diagnosis, and natural history Food Tech. 1992 141-144
36. R.R. Scheline Metabolism of foreign compounds by gastrointestinal microorganisms Pharmacol Rev. 25 1973 451-523
37. J.H. Cumings H.N. Englyst Fermentation in the human large intestine Evidence and implications for health Lancet 45 5 Suppl 1983 1206-1208
38. R.A. McKinnon M.E. McManus Localization of cytochromes P450 in human tissues Implications for chemical toxicity Pathology 28 1996 148-155
39. R.A. McKinnon W.M. Burgess P.M. Hall et. al. Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues Gut 36 1995 259-267
40. Benet L. 27th Gordon research conference on drug metabolism. July 6-13, 1997, personal communication.
41. K.V. Chin I. Pastan M.M. Gottesman Function and regulation of the multidrug resistance gene Adv Cancer Res. 60 1993 157-180
42. K.S. Bauer J.E. Karp T.S. Garimella et. al. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia Leuk Res. 29 3 2005 263-271
43. A.S. Planting P. Sonneveld A. van der Gaast et. al. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors Cancer Chemother Pharmacol. 55 1 2005 91-99
44. J.E. Kolitz S.L. George R.K. Dodge et. al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621 J Clin Oncol. 22 21 2004 4290-4301
45. A. Larkin E. Moran D. Alexander M. Clynes Preliminary immuno-cytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias Adv Exp Med Biol. 457 1999 65-70
46. A. Larkin E. Moran D. Alexander et. al. A new monoclonal antibody that specifically recognises the MDR-3-encoded gene product Int J Cancer 80 2 1999 265-271
47. B.K. Park N.R. Kitteringham M. Pirmohamed G.T. Tucker Relevance of induction of human drug-metabolizing enzymes pharmacological and toxicological implications Br J Clin Pharmacol. 41 1996 477-491
48. M.A. Kall J. Clausen Dietary effect on mixed function P450 1A2 activity assayed by estimation of cafffeine metabolism in man Hum Exp Toxicol. 14 1995 801-807
49. W.D. Parsons A.H. Neims Effect of smoking on caffeine clearance Clin Pharmacol Ther. 24 1978 40-45
50. F.P. Guengerich Effects of nutritive factors on metabolic processes involving bioactivation and detoxification of chemicals Ann Rev Nutr. 4 1984 207-231
51. M.M. Manson H.W. Ball M.C. Barrett et. al. Mechanism of action of dietary chemoprotective agents in rat liver: Induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism Carcinogenesis 18 1997 1729-1738
52. D.H. Barch L.M. Rundhaugen N.S. Pillay Ellagic acid induces tran-scription of the rat glutathione S-transferase-Ya gene Carcinogenesis 16 1995 665-668
53. E.J. Pantuck C.B. Pantuck W.A. Garland et. al. Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism Clin Pharm Ther. 25 1979 88-95
54. E.A. Offord K. Mace C. Ruffieux et. al. Rosemary components inhibit benzo[a]pyreneinduced genotoxicity in human bronchial cells Carcinogenesis 16 1995 2057-2062
55. C. Ip D.J. Lisk Modulation of phase I and phase II xenobiotic-metabolizing enzymes by selenium-enriched garlic in rats Nutr Cancer 28 1997 184-188
56. L.C. Appelt M.M. Reicks Soy feeding induces phase II enzymes in rat tissues Nutr Cancer 28 1997 270-275
57. S.G. Van Breda E. van Agen L.G. Engels et. al. Altered vegetable intake affects pivotal carcinogenesis pathways in colon mucosa from adenoma patients and controls Carcinogenesis 25 11 2004 2207-2216
58. E.F. Lhoste K. Gloux I. De Waziers et. al. The activities of several detoxication enzymes are differentially induced by juices of garden cress, water cress and mustard in human HepG2 cells Chem Biol Interact. 150 3 2004 211-219
59. V. Elangovan N. Sekar S. Govindasamy Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesis Cancer Lett. 87 1994 107-113
60. T.J. Smith C.S. Yang Effects of food phytochemicals on xenobiotic metabolism and tumorigenesis Food Phytochemicals I: Fruits and Vegetables 1994 American Chemical Society Press Washington, DC 17-48
61. E.B. Feldman How grapefruit juice potentiates drug availability Nutr Rev. 55 1997 398-400
62. A. Weber R. Jager A. Borner et. al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 53 1996 41-47
63. Mulder GJ. Sulfate availability in vivo. In: Mulder GJ, ed. Sulfation of drugs and related compounds. Boca Raton, FL: CRC Press, Inc; pp. 31-52.
64. F. Gonzalez H. Gelboin Role of human cytochrome P450s in risk assessment and susceptibility to environmentally based disease J Toxicol Environ Health 40 1993 289-308
65. T. Dervieux B. Meshkin B. Neri Pharmacogenetic testing proofs of principle and pharmacoeconomic implications Mutat Res. 573 1-2 2005 180-194
66. D. Allorge M.A. Loriot Pharmacogenetics or the promise of a per-sonalized medicine: Variability in drug metabolism and transport Ann Biol Clin (Paris) 62 5 2004 499-511
67. R. Waring P. Emery The genetic origin of responses to drugs Br Med Bull. 51 1995 449-461
68. A. Gaedigk M. Blum R. Gaedigk et. al. Deletion of the entire cyto-chrome P450 CYP2D6 gene as a cause of impaired drug metabo-lism in poor metabolizers of the debrisoquine/sparteine polymorphism Am J Hum Genet. 48 1991 943-950
69. U.A. Meyer U.M. Zanger R.C. Skoda et. al. Genetic polymorphisms of drug metabolism Prog Liver Dis. 9 1990 307-323
70. D. Iarbovici Single blood test might predict drugs' effects on patients J NIH Res. 9 1997 34-45
71. W. Weber Influence of heredity on human sensitivity to environ-mental chemicals Environ Mol Mutagen 25 Suppl 26 1995 102-114
72. J.D. Hayes R.C. Strange Glutathione S-transferase polymorphisms and their biological consequences Pharmacology 61 2000 154-166
73. X. Ponsoda M.T. Donato G. Perez-Cataldo et. al. Drug metabolism by cultured human hepatocytes: How far are we from the in vivo reality? Altern Lab Anim. 32 2 2004 101-110
74. F.P. Guengerich Cytochrome P450 what have we learned and what are the future issues? Drug Metab Rev. 36 2 2004 159-197
75. B. Vallee The function of metallothionein Neurochem Int. 27 1995 23-33
76. M. Aschner M. Cherian C. Klaassen et. al. Metallothioneins in brain - the role in physiology and pathology Toxicol Appl Pharmacol. 142 1997 229-242
77. A. Chopra J. Thibordeau Y. Tam et. al. New mouse somatic cell mutants resistant to cadmium affected in the expression of their metallothionein genes J Cell Physiol. 142 1990 316-324
78. M. Sato M. Kondoh Recent studies on metallothionein protection against toxicity of heavy metals and oxygen free radicals Tohoku J Exp Med. 196 2002 9-22
79. Y. Kondo E. Woo A. Michalska et. al. Metallothionein null cells have increased sensitivity to anticancer drugs Cancer Res. 55 1995 2021-2023
80. G.J. Brewer Zinc therapy induction of intestinal metallothionein in Wilson's disease Am J Gastroenterol. 94 1999 301-302
81. K. Sullivan F.R. Burnett R.J. Cousins Metallothionein expression is increased in monocytes and erythrocytes of young men during zinc supplementation J Nutr. 128 1998 707-713
82. S. Bobillier Chaumont V. Maupoil J. Jacques Lahet A. Berthelot Effect of exercise training on metallothionein levels of hypertensive rats Med Sci Sports Exerc. 33 2001 724-728
83. M. Kondoh K. Kamada M. Kuronaga et. al. Antioxidant property of metallothionein in fasted mice Toxicol Lett. 143 2003 301-306
84. W.D. Pennie J.D. Tugwood G.J. Oliver I. Kimber The principles and practice of toxigenomics: Applications and opportunities Toxicol Sci. 54 2 2000 277-283
85. L.Z. Benet D.L. Kroetz L.B. Sheiner Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination P.B. Milinoff R.W. Ruddon A. Goodman Gilman The Pharmacological Basis of Therapeutics 9th ed. 1996 McGraw-Hill New York, NY 3-27
86. S.R. Burzynski Aging: Gene silencing or gene activation? Med Hypotheses 64 1 2005 201-208
87. D. Gems J.J. McElwee Broad spectrum detoxification: The major longevity assurance process regulated by insulin/IGF-1 signaling? Mech Ageing Dev. 126 3 2005 381-387
88. L.E. Gustavson L.Z. Benet Menopause: Pharmacodynamics and pharmacokinetics Exp Gerontol. 29 1994 437-444
89. Benet LZ. 27th Gordon research conference on drug metabolism. July 6-13, 1997, personal communication.
90. A. Rannug A.K. Alexandrie I. Persson M. Ingelman-Sundberg Genetic polymorphism of cytochromes P450 1A1, 2D6, and 2E1: Regulation and toxicological significance J Occupational Environ Med. 37 1995 25-36
91. M.J.J. Ronis K.O. Lindros M. Ingelman-Sundberg The CYP2E subfamily C. Ioannides, Cytochromes P450: Metabolic and Toxicological Aspects 1996 CRC Press, Inc; Boca Raton, FL 211-239
92. E. Miller J. Miller Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules Cancer 47 1981 2327
93. J.A. Agundez M.C. Ledesma J. Benitiz CYP2D6 genes and risk of liver cancer Lancet 345 8953 1995 830-831
94. K. Kawajiri K. Nakaji K. Imai et. al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene FEBS Lett. 263 1990 131
95. B. Ketterer J.M. Harris G. Talaska et. al. The human glutathione S-transferase supergene family, its polymorphism, and low level environmental exposure to carcinogens Nature 369 1994 154-156
96. U. Meyer U. Zanger D. Grant et. al. Genetic polymorphisms of drug metabolism Adv Drug Res. 19 1990 97-241
97. R.J. Goldberg The P450 system Arch Fam Med. 5 1996 406-412
98. J. Lazarou B.H. Pomeranz P.N. Corey Incidence of adverse drug reactions in hospitalized patients JAMA 279 1998 1200-1217
99. D. Iarbovici Single blood test might predict drugs' effects on patients J NIH Res. 9 1997 34-45
100. K.A. Phillips S.L. Van Bebber Measuring the value of pharmacogenomics Nat Rev Drug Discov. 4 6 2005 500-509
101. J.K. Breaux G. Los Gene expression profiling to characterize anti-cancer drug sensitivity Methods Mol Med. 111 2005 197-231
102. T. Efferth M. Volm Pharmacogenetics for individualized cancer chemotherapy Pharmacol Ther. 107 2 2005 155-176
103. J. Kirchheiner K. Nickchen M. Bauer et. al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic vari-ations to the phenotype of drug response Mol Psychiatry 9 5 2004 442-374
104. National Research Council Environmental Neurotoxicology 1992 National Academy Press; Washington, D.C
105. National Research Council Biologic Markers in Immunotoxicology 1992 National Academy Press; Washington, D.C
106. J. Schubett E.J. Riley S.A. Tyler Combined effects of toxicology - a rapid systematic testing procedure: Cadmium, mercury, and lead J Toxicol Environ Health 4 1978 763-776
107. W.J. Rea Chemical Sensitivity Vol. 4 1997 CRC Press, Inc. Boca Raton, Fla 1011-1067
108. W.J. Rea N. Didriksen T.R. Simon et. al. Effects of toxic exposure to molds and mycotoxins in building-related illnesses Arch Environ Health 58 7 2003 399-405
109. B.A. Neuschwander-Tetri Common blood tests for liver disease. Which ones are most useful? Postgrad Med 98 1 1995 49-63
110. A.J. Quick The synthesis of hippuric acid: A new test of liver function Am J Med Sci. 185 1933 630-637
111. B.K. Park N.R. Kitteringham M. Pirmohamed G.T. Tucker Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications Br J Clin Pharmacol. 41 1996 477-491
112. M. Patel B.K. Tang W. Kalow Variability of acetaminophen metabolism in Caucasians and Orientals Pharmacogenetics 2 1992 38-45
113. G. Levy Pharmacokinetics of salicylate elimination in man J Pharmaceutical Sci. 54 1965 959-967
114. B. Fulton E. Jeffery The temporal relationship between hepatic GSH loss, heme oxygenase induction, and cytochrome P450 loss following intraperitoneal aluminum administration to mice Toxicol Appl Pharmacol. 127 1994 291-297
115. C. Lieber Alcohol, liver, and nutrition J Am Coll Nutr. 10 6 1991 602-632
116. F. Guengerich Effects of nutritive factors on metabolic processes involving bioactivation and detoxication of chemicals Ann Rev Nutr. 4 1984 207-231
117. M. Kall J. Clausen Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man Human Exp Toxicol. 14 10 1995 801-807
118. K. Anderson Dietary regulation of cytochrome P450 Annu Rev Nutr. 11 1991 141-167
119. S. Jaw E. Jeffery Interaction of caffeine with acetaminophen Biochem Pharmacol. 46 3 1993 493-501
120. W. Parsons A.H. Neims Effect of smoking on caffeine clearance Clin Pharmacol Ther. 24 1978 40-45
121. K. Setchel M. Welsh M. Klooster et. al. Rapid high-performance liquid chromatography assay for salivary and serum caffeine following an oral load-an indicator of liver function J Chromatogr. 385 1987 267-274
122. J. Brockmoller I. Roots Assessment of liver metabolic function Clin Pharmacokinet Concepts 27 3 1994 216-247
123. G. Jost A. Wahllander R. Von Mandach R. Preisig Overnight sali-vary caffeine clearance: A liver function test suitable for routine use Hepatology 7 2 1987 338-344
124. M. Patel B. Tang W. Kalow Variability of acetaminophen metabolism in Caucasians and Orientals Pharmacogenetics 2 1992 38-45
125. D.C. Whitcomb G. Block Association of acetaminophen hepatotoxicity with fasting and ethanol use JAMA 272 23 1994 845-509
126. A. Hutt J. Caldwell R. Smith The metabolism of aspirin in man: A population study Xenobiotica 16 3 1986 239-249
127. A.J. Quick The synthesis of hippuric acid: A new test of liver function Am J Med Sci. 185 1933 630-637
128. M. Patel B. Tang W. Kalow Variability of acetaminophen metabolism in Caucasians and Orientals Pharmacogenetics 2 1992 38-45
129. J.E. Pizzorno M.T. Murray Detoxification: A naturopathic perspective Nat Med J. 1 1998 6-17
130. G.S. Shukla R.L. Singhal The present status of biological effects of toxic metals in the environment: Lead, cadmium, and manganese Can J Physiol Pharmacol. 62 1984 1015-1031
131. A. Gyurasics et. al. Increased biliary excretion of glutathione is generated by the glutathione-depletion hepatobiliary transport of antimony and bismuth Biochem Pharmacol. 44 1992 1275-1281
132. S. Foo et. al. Metals in hair as biological indices for exposure Int Arch Occup Environ Health 65 1993 S83-S86
133. M. Davies Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis J Hepatol. 22 5 1995 551-560
134. H. Bradley Sulfate metabolism is abnormal in patients with rheu-matoid arthritis: Confirmation by in vivo biochemical findings J Rheumatol. 217 1994 1192-1196
135. W. Rea Chemical Sensitivity 4 1997 CRC Press Boca Raton, FL 2052-2060
136. M. Black B. Billings Hepatic bilirubin UDP-glucuronyl transferase activity in liver disease and Gilbert's syndrome New Engl J Med. 280 1969 1266-1271
137. S. De Morais J. Uetecht P. Wells Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome Gastroenterology 102 1992 577-586
138. N. Mendez-Sanchez M. Martinez V. Gonzalez et. al. Zinc sulfate inhibits the enterohepatic cycling of unconjugated bilirubin in subjects with Gilbert's syndrome Ann Hepatol. 1 1 2002 40-43
139. D. Rigden J.A. Bralley J. Bland Nutritional upregulation of hepatic detoxification enzymes J Appl Nutr. 44 3&4 1992 2-15
140. R.A. Bulst Chronic fatigue syndrome and chemical overload Int Clin Nutr Rev. 8 4 1988 173-175
141. S. Rigden Entero-Hepatic resuscitation program for CFIDS. The CFIDS Chronicle Spring 1995 46-49
142. J. Bland E. Barrager R.G. Reedy K. Bland A medical food supple-mented detoxification program in the management of chronic health problems Altern Ther Health Med. 1 5 1995 62-71
143. W.T. Hamilton A.M. Gallagher J.M. Thomas P.D. White The prognosis of different fatigue diagnostic labels: A longitudinal survey Fam Pract. 22 4 2005 383-388
144. K.A. Rimes T. Chalder Treatments for chronic fatigue syndrome Occup Med (London) 55 1 2005 32-39
145. M.J. Huibers G. Bleijenberg L.G. van Amelsvoort et. al. Predictors of outcome in fatigued employees on sick leave: Results from a ran-domised trial J Psychosom Res. 57 5 2004 443-449
146. R.V. Burim et. al. Polymorphisms in glutathione S-transferases GSTM1, GSTT1 and GSTP1 and cytochromes P450 CYP2E1 and CYP1A1 and susceptibility to cirrhosis or pancreatitis in alcoholics Mutagenesis 19 4 2004 291-298
147. P. Soderkvist A. Ahmadi Glutathione S-transferase M1 null geno-type as a risk modifier for solvent-induced chronic toxic encephalopathy Scand J Work Environ Health 22 1996 360-363
148. J.M. Braganza J.E. Jolley et. al. Occupational chemicals and pancreatitis: A link? Int J Pancreatol. 1 1986 9-19
149. G.B. Steventon M.T. Heafield R.H. Waring A.C. Williams Xenobiotic metabolism in Parkinson's disease Neurology 39 1989 883-887
150. M.T. Heafield S. Fearn G.B. Steventon et. al. Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease Neurosci Lett. 110 1990 216-220
151. D. Perlmutter Parkinson's diseases - new perspectives Townsend Newslett. 1997 48-50
152. G.B. Steventon M.T. Heafield R.H. Waring A.C. Williams Xenobiotic metabolism in Parkinson's disease Neurology 39 1989 883-887
153. J.M. Wi Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers J Natl Cancer Inst. 83 3 1991 963
154. R.A. McKinnon D.W. Nebert Possible role of cytochromes P450 in lupus erythematosus and related disorders Lupus 3 1994 473-478
155. R.C. Dougherty et. al. Negative chemical ionization studies of human and food chain contamination with xenobiotic chemicals Environ Health Perspect. 36 1980 103-117
156. C.S. Chang S.S. Liao Topographic recognition of cyclic hydrocar-bons and related compounds by receptors for androgens, estro-gens, and glucocorticoids J Steroid Biochem 27 1987 123-131
157. E.J. Calabrese Toxicological consequences of multiple chemical interactions: A primer Toxicology 105 1995 121-135
158. J. Michnovicz Environmental modulation of oestrogen metabolism in humans Int Clin Nutr Rev. 7 4 1987 169-173
159. A. Temelli S. Mogavero P.C. Giulianotti et. al. Conjugation of benzoic acid with glycine in human liver and kidney: A study on the interindividual variability Xenobiotica 23 12 1993 1427-1433
160. U. Meyer U. Zanger D. Grant et. al. Genetic polymorphisms of drug metabolism Adv Drug Res. 19 1990 197-241
161. R.J. Williams Biochemical individuality: The basis of the gene-totrophic concept 1956 John Wiley New York
162. F.E. Goldin I.D. Tatnayaka Acetaminophen and macrophage activation Int Hepato Comms. 4 1995 16-18